A new council aims to make aging a curable goal, using AI to move from reactive care to longer, healthier lives.
What if medicine stopped chasing diseases and started chasing time? For much of modern healthcare, the script has been predictable: wait for something to go wrong, then treat it. A diagnosis is made, then a medicine. But what if the real target is not the disease? What if it’s the slow, underlying process that makes these diseases more likely in the first place?
Here are the questions Insilico Medicine by launching what it calls the industry’s first Longevity Council, a group dedicated to guiding how artificial intelligence can be used to develop drugs that not only treat disease but also interfere with aging itself (1). Instead of fixing things as they break, try to slow down the biological wear and tear that causes the breakdown in the first place.
At the heart of the move is Eli Lilly and Company’s Andrew Adams, who chairs the board. Longevity Science has lived in two separate worlds for years. On the one hand, researchers are studying the deep biology of aging—complex, promising, but often difficult to translate into real drugs. On the other hand, big pharmaceutical companies that know how to market drugs, but don’t always prioritize aging as a target.
Adams is seated at center right. His appointment shows that longevity is no longer satisfied with research curiosity. It wants to be a product that is configurable, scalable and established. This changes the stakes, because when longevity enters pharmaceutical engineering, it is no longer just about possibility.
The phrase “resilience” has always had a certain baggage – over-promise, under-deliver, often into the realm of wishful thinking. What is emerging now is more pragmatic. Instead of trying to “reverse aging,” companies like Insilico focus on the conditions that lie alongside it: obesity, muscle loss, metabolic disorders, fibrosis, and even chronic disease.
Diseases are also an expression of how the body changes over time. Think of aging as a system that slowly loses caliber. Different parts move at different speeds, but they are all connected.
Insilico’s strategy is to identify what it calls “dual targets,” biological pathways that affect both disease and aging. If you can regulate these pathways, you’re not just treating a condition; you are likely to bring the entire system back into balance. It’s not a shortcut, but it’s a path that regulators, investors, and clinicians can actually follow.
Aging is messy. It doesn’t happen in one place or for one reason. It’s a network problem—genes, proteins, cells, and environments all interact in ways that are hard to unravel. This is where AI becomes necessary. Imagine trying to map a city by walking every street on your own. Now imagine having a satellite view that shows traffic patterns, obstacles, and hidden connections all at once. This is what AI is trying to bring to drug discovery.
By processing large amounts of biological data, AI can identify patterns that would take humans years (if not decades) to detect. It can suggest which goals are worth pursuing, which combinations might work, and which paths are likely to be dead ends.
For Insilico, the Longevity Board, which includes the CEO and CEO of the company, is about making sure that this computing power is focused in the right direction and based on real biology.
A groundbreaking decade now taking shape
For Michael Levitt, who joins the Board, the moment reflects how far the field has come and how far it needs to go.
“The science of longevity has matured tremendously since Alex and I began working together over a decade ago. What excites me about this Board is the combination of precise biological understanding with massive computing power that can really move the needle.”
Levitt expressed his view that aging should not be viewed as an isolated problem, but rather as a complex and deeply interconnected network of molecular and cellular processes. He emphasized that the only real possibility of extending human life and human health lies in systematically addressing this complexity using AI tools capable of mapping such complex systems.
Moreover, he also expressed pride in contributing to an initiative he described as scientifically sound, serious and ambitious enough to achieve meaningful results. His point is clear: aging is not something you can “fix.” It’s a system you have to understand well enough to make an impact, and it takes both patience and scale.
Now where does this leave longevity
The creation of the Longevity Council may seem like an internal move, but it reflects broader changes across the industry. It is becoming organized, structured and responsible.
Perhaps that is what has been lacking throughout this industry. Extending life isn’t just about adding years; it’s about keeping people healthier, delaying the onset of illness, shortening the period of decline. What Insilico builds is not a breakthrough, but a framework, a way to transform a long-lived idea into a pipeline.
If it succeeds, the effect will be gradual, almost invisible – less chronic conditions, later in life; treatments that look less like rescue and more like care. In other words, the shift from responding to aging … to managing it. That, more than anything else, is what makes this moment feel new. We ultimately approach it as something we can do consistently and at scale.
Photo courtesy of Insilico Medicine
(1) https://insilico.com/news/vxuidy8ph1-insilico-medicine-announces-industrys-fi
